Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Eqrx Inc (EQRX)
Eqrx Inc (EQRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 884,371
  • Shares Outstanding, K 488,603
  • Annual Sales, $ 0 K
  • Annual Income, $ -169,090 K
  • 60-Month Beta 0.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.63
Trade EQRX with:

Options Overview Details

View History
  • Implied Volatility 124.12% ( +124.12%)
  • Historical Volatility 49.09%
  • IV Percentile 50%
  • IV Rank 15.06%
  • IV High 595.89% on 01/06/23
  • IV Low 40.49% on 07/13/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 10.56
  • Today's Open Interest 10,747
  • Open Int (30-Day) 10,921

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7200 +9.16%
on 03/24/23
2.3100 -18.72%
on 03/06/23
-0.3825 (-16.92%)
since 02/28/23
3-Month
1.7200 +9.16%
on 03/24/23
2.9700 -36.78%
on 01/06/23
-0.3225 (-14.66%)
since 12/28/22
52-Week
1.7200 +9.16%
on 03/24/23
6.0500 -68.97%
on 08/11/22
-2.1225 (-53.06%)
since 03/28/22

Most Recent Stories

More News
Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study

Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candidate demonstrated a robust glucose-lowering response in patients with type II diabetes.

CRSP : 45.15 (+2.96%)
CERT : 23.86 (+0.25%)
BMEA : 32.26 (+5.05%)
EQRX : 1.8900 (+4.42%)
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer

Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.

CRSP : 45.15 (+2.96%)
JNCE : 1.8450 (+0.27%)
CERT : 23.86 (+0.25%)
EQRX : 1.8900 (+4.42%)
Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal

Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.

NVO : 156.57 (+0.80%)
RCEL : 13.56 (+0.22%)
AVTX : 1.6500 (-5.17%)
EQRX : 1.8900 (+4.42%)
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data

Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate....

ALT : 4.37 (-1.13%)
RCEL : 13.56 (+0.22%)
AVTX : 1.6500 (-5.17%)
EQRX : 1.8900 (+4.42%)
After Plunging -17.33% in 4 Weeks, Here's Why the Trend Might Reverse for EQRx, Inc. (EQRX)

EQRx, Inc. (EQRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...

EQRX : 1.8900 (+4.42%)
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates

Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.

ADPT : 8.44 (+2.43%)
BLCM : 0.3025 (+16.35%)
CRSP : 45.15 (+2.96%)
EQRX : 1.8900 (+4.42%)
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences

Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.

ADPT : 8.44 (+2.43%)
CRSP : 45.15 (+2.96%)
JNCE : 1.8450 (+0.27%)
EQRX : 1.8900 (+4.42%)
Catalyst (CPRX) to Report Q4 Earnings: What's in the Cards?

Revenues of Catalyst Pharmaceuticals (CPRX) are expected to have been driven by the sales of its only marketed product, Firdapse, for treating LEMS, along with the drug's label expansion for the treatment...

CPRX : 16.69 (+1.95%)
TBPH : 10.71 (+1.23%)
ASRT : 6.30 (+0.64%)
EQRX : 1.8900 (+4.42%)
Ardelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store?

Ardelyx (ARDX) is expected to report better-than-expected sales growth of its only marketed product, Ibsrela (tenapanor) and provide an update on the NDA resubmission timeline for Xphozah, tenapanor.

ARDX : 4.65 (+10.19%)
FGEN : 19.42 (+3.24%)
ASRT : 6.30 (+0.64%)
EQRX : 1.8900 (+4.42%)
Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat

Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.

ALT : 4.37 (-1.13%)
ZTS : 162.60 (-1.48%)
ALVR : 4.22 (+5.24%)
EQRX : 1.8900 (+4.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

EQRx Inc. is a pharmaceutical company is involved in developing and delivering medicines to patients. EQRx Inc., formerly known as CM Life Sciences III, is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 1.9667
2nd Resistance Point 1.9233
1st Resistance Point 1.8667
Last Price 1.8900
1st Support Level 1.7667
2nd Support Level 1.7233
3rd Support Level 1.6667

See More

52-Week High 6.0500
Fibonacci 61.8% 4.3959
Fibonacci 50% 3.8850
Fibonacci 38.2% 3.3741
Last Price 1.8900
52-Week Low 1.7200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar